Drugs

HTA ID	Drug	Brand	Indication	Assessment status	Date
19039	Liraglutide	Saxenda®	As an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial body mass index (BMI) of ≥30kg/m2 (obese), or ≥27kg/m2 to <30kg/m2 (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea. The Applicant is seeking reimbursement in a subgroup of the licensed population, that is,  as an adjunct to a reduced calorie diet and increased physical activity for weight management in adult patients with an initial body mass index of ≥35kg/m2 with pre-diabetes and high risk of cardiovascular disease.	Assessment process complete	10th February 2021
-	Liraglutide	Victoza®	For treatment of adults with type 2 diabetes mellitus.	Assessment process complete	7th March 2019
-	Lisdexamfetamine dimesylate	Tyvense®	For Attention Deficit Hyperactivity Disorder in children aged 6 years and over when response to previous methylphenidate treatment is considered clinically inadequate.	Rapid Review Complete	28th February 2013
__	__	__	__	__	7th August 2014
-	Lomitapide	Lojuxta®	As an adjunct to a low-fat diet and other lipid-lowering medicinal products with or without low density lipoprotein (LDL) apheresis in adult patients with homozygous familial hypercholesterolaemia (HoFH).	Rapid Review Complete	15th September 2014
23053	Loncastuximab tesirine	Zynlonta®	Loncastuximab tesirine (Zynlonta®) is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy.	Rapid Review Complete	1st September 2023
-	Lorlatinib	Lorviqua®	As monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC), following disease progression on: (i) alectinib or ceritinib as the first ALK-targeted treatment, or (ii) crizotinib and at least one other ALK-targeted treatment.	Rapid Review Complete	25th June 2019
21071	Lorlatinib	Lorviqua®	As monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.	Rapid Review Complete	13th January 2022
-	Lornoxicam	Xefo®	For the short-term relief of acute mild to moderate pain and symptomatic relief of pain and inflammation in osteoarthritis and symptomatic relief of pain and inflammation in rheumatoid arthritis	Rapid Review Complete	7th July 2011
-	Loteprednol	Lotemax 0.5% eye drops suspension	For treatment of post-operative inflammation following ocular surgery.	Rapid Review Complete	5th December 2011
-	Loxapine inhalation powder	Adasuve®	For the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder.	Rapid Review Complete	28th July 2016
-	Lumacaftor/ivacaftor	Orkambi®	For the treatment of cystic fibrosis (CF) in patients aged 12 years and older who are homozygous for the F508del mutation in the CFTR gene.	Assessment process complete	1st June 2016
-	Lutetium (177Lu) Oxodotreotide	Lutathera®	For the treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor (SSTR) positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults.	Assessment process complete	11th February 2020
23002	Lutetium (177Lu) vipivotide tetraxetan	Pluvicto®	Lutetium (177Lu) vipivotide tetraxetan in combination with androgen deprivation therapy (ADT) with or without androgen receptor (AR) pathway inhibition for the treatment of adult patients with progressive prostate specific membrane antigen (PSMA) positive metastatic castration resistant prostate cancer (mCRPC) who have been treated with AR pathway inhibition and taxane based chemotherapy.	Full HTA submission received from Applicant	19th July 2023
22062	Macimorelin acetate	Ghryvelin®	For the diagnosis of growth hormone deficiency (GHD) in adults.	Rapid Review Complete	4th October 2022
-	Macitentan	Opsumit®	Macitentan is indicated as monotherapy or in combination, for the long term treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III.	Rapid Review Complete	31st January 2014
-	Magnesium Aspartate Dihydrate	Magnaspartate®	For the treatment and prevention of magnesium deficiency as diagnosed by a doctor. Magnaspartate is indicated in adults, children and adolescents aged from 2 years.	Rapid Review Complete	14th May 2019
-	Mannitol Dry Powder	Bronchitol®	Mannitol dry powder for inhalation for the treatment of cystic fibrosis (CF)	Assessment Process Complete	29th April 2019
22069	Maribavir	Livtencity®	For the treatment of cytomegalovirus (CMV) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant or solid organ transplant.	Rapid Review Complete	13th December 2022
23028	Mavacamten	Camzyos®	Mavacamten (Camzyos®) is indicated for the treatment of symptomatic (New York Heart Association, NYHA, class II–III), obstructive hypertrophic cardiomyopathy (oHCM) in adult patients.	Awaiting full HTA submission from Applicant	12th September 2023
-	Melatonin	Circadin®	Prolonged release melatonin (Circadin®) for the short-term treatment of primary insomnia.	Full HTA Assessment	21st October 2008
22048	Melatonin	Slenyto®	For the treatment of insomnia in children and adolescents aged 2-18 with Autism Spectrum Disorder (ASD) and / or Smith-Magenis syndrome (SMS), where sleep hygiene measures have been insufficient.	Rapid Review Complete	9th August 2022
-	Mepolizumab	Nucala®	Is indicated as an add-on treatment for severe refractory eosinophilic asthma in adult patients.	Assessment Process Complete	1st March 2017
-	Mepolizumab	Nucala®	Mepolizumab 100mg solution in pre-filled pen and mepolizumab 100mg solution in pre-filled syringe are indicated for severe refractory eosinophilic asthma in adults and adolescents aged 12 years and over.	Rapid Review Complete	5th November 2019
20007	Meropenem/vaborbactam	Vaborem®	Is indicated for the treatment of the above infections in adults.	Rapid Review Complete	2nd April 2020
-	Methoxyflurane	Penthrox®	For the emergency relief of moderate to severe pain in conscious adult patients with trauma and associated pain.  It is an inhaled anesthetic with analgesic effects at sub-anesthetic doses.	Rapid Review Complete	18th December 2015
19049	Methyl aminolevulinate	Metvix®	For the treatment of: thin or non-hyperkeratotic and non-pigmented actinic keratoses on the face and scalp, when other therapies are considered less appropriate; superficial and/or nodular basal cell carcinoma unsuitable for other available therapies; and squamous cell carcinoma in situ (Bowen´s disease) when surgical excision is considered less appropriate.	Rapid Review Complete	18th December 2019
-	Midostaurin	Rydapt®	Is indicated in combination with standard daunorubicin and cytarabine induction and high dose cytarabine consolidation chemotherapy, and for patients in complete response followed by midostaurin single agent maintenance therapy, for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3 mutation positive.	Assessment Process Complete	5th December 2019
-	Midostaurin	Rydapt®	Midostaurin is indicated as monotherapy for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated haematological neoplasm (SM AHN), or mast cell leukaemia (MCL).	Suspended	16th October 2018
-	Mifamurtide	Mepact®	For the treatment of osteosarcoma.	Rapid Review Complete	13th July 2010
-	Migalastat	Galafold®	For the long term treatment of adult and adolescent patients 16 years and older with a confirmed diagnosis of Fabry disease and who have an amenable mutation.	Assessment Process Complete	1st June 2017
-	Mirabegron	Betmiga®	Symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome.	Rapid Review Complete	12th March 2013
23040	Mirikizumab	Omvoh®	Mirikizumab (Omvoh®) is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment.	Rapid Review Complete	24th August 2023
-	Modified Release Hydrocortisone	Plenadren®	For the treatment of adrenal insufficiency in adults.	Assessment process complete	1st January 2018
20061	Mogamulizumab	Poteligeo®	For the treatment of adult patients with mycosis fungoides or Sézary syndrome who have received at least one prior systemic therapy.	NCPE Assessment Process Complete	6th July 2023
21060	Molnupiravir	Lagevrio®	For the treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19.	Rapid Review Complete	24th December 2021
21051	Mometasone furoate plus olopatadine	Ryaltris®	Is indicated for the treatment of moderate to severe nasal symptoms associated with allergic rhinitis in adults and adolescents aged 12 years and older.	Rapid Review Complete	22nd December 2021
23023	Mosunetuzumab	Lunsumio®	Mosunetuzumab (Lunsumio®) as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma who have received at least two prior systemic therapies.	Awaiting full HTA submission from Applicant	4th July 2023
-	Nab-paclitaxel	Abraxane®	In combination with gemcitabine is indicated for the first-line treatment of adult patients with metastatic adenocarcinomoa of the pancreas.	Assessment Process Complete	5th September 2014
-	Nalmefene	Selincro®	Is indicated for the reduction of alcohol consumption in those aged ≥18 years with alcohol dependence, who do not require immediate detoxification.	Assessment Process Complete	8th April 2014
-	Naloxegel	Moventig®	Is indicated for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s).	Rapid Review Complete	13th April 2015
20019	Naloxone	Nyxoid®	Intranasal spray is intended for immediate administration as emergency therapy for known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression in both non-medical and healthcare settings. Nyxoid® is indicated in adults and adolescents aged 14 years and over. Nyxoid® is not a substitute for emergency medical care.	Rapid Review Complete	12th May 2020
-	Naltrexone / bupropion	Mysimba®	Is indicated, as an adjunct to a reduced-calorie diet and increased physical activity, for the management of weight in adult patients (≥ 18 years) with a BMI of ≥30 kg/m2 (obese) or ≥27 kg/m2 (overweight) in the presence of one or more weight-related co-morbidities.	Assessment Process Complete	9th May 2018
-	Natalizumab	Tysabri®	For the treatment of relapsing remitting multiple sclerosis that is rapidly evolving and severe or sub-optimally treated.	Full HTA Assessment	27th April 2007
-	Nepafenac	Nevanac®	For the prevention and treatment of postoperative pain and inflammation associated with cataract surgery.	Rapid Review Complete	27th June 2011
19057	Neratinib	Nerlynx®	For the extended adjuvant treatment of adults with early-stage hormone receptor-positive, HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.	Assessment Process Complete	12th May 2021
-	Netupitant/palonosetron	Akynzeo®	For the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and for prevention of acute and delayed nausea and vomiting associated with moderately emetogenic cancer chemotherapy.	Rapid Review Complete	13th October 2015
-	Nilotinib CML resistant/intolerant to imatinib	Tasigna®	For the treatment of chronic phase CML.	Full HTA Assessment	25th February 2008
-	Nilotinib	Tasigna®	For the newly diagnosed Chronic Phase Philadelpha Chromosone positive CML.	Rapid Review Complete	22nd October 2010
-	Nintedanib	Ofev®	Indicated in adults for the treatment of Idiopathic Pulmonary Fibrosis (IPF).	Assessment Process Complete	22nd February 2016